APLX

APLX, developed by Helix, is a chemotherapeutic drug used in the treatment of certain blood cancers, notably acute myeloid leukemia (AML). It is a form of arsenic trioxide administered intravenously, which works by inducing cancer cell death and promoting the differentiation of immature cells into normal blood cells. APLX has been effective in improving remission rates and survival in patients with AML, especially those with a specific genetic abnormality called acute promyelocytic leukemia. Its targeted action and established safety profile make it a valuable option in modern leukemia treatment protocols.